Krystal Biotech stock performance snapshot

Krystal Biotech (KRYS) has attracted fresh attention after recent share price gains, with the stock closing at $346.58 on 19 August 2026. Investors are weighing these moves against its recent return profile and fundamentals.

Over the past month the stock shows a 3.4% return, with about 15.7% in the past 3 months and 40.4% year to date. Its 1 year total return is 130.3%, while the 3 year figure is approximately 1.7 times and the 5 year total return is about 5 times.

Across timeframes, Krystal Biotech shows strong momentum, with a 7 day share price return of 4.31% and a 1 year total shareholder return of 130.31% reinforcing interest around the recent move.

If Krystal Biotech's performance has you looking beyond a single stock, this is a good moment to scan the wider healthcare opportunity set with our 40 healthcare AI stocks.

After such a strong run and a market value of about US$10.3b built on a single commercial product and pipeline promise, does Krystal Biotech still offer a compelling risk reward for new buyers at around US$346 a share?

Most Popular Narrative: 10% Undervalued

On the most widely followed narrative, Krystal Biotech's fair value sits at $385 per share compared with the recent close at $346.58. That gap reflects a view that the current price does not fully reflect the earnings and revenue outlook implied by its genetic medicines franchise.

The expansion of Krystal's pipeline, including imminent and near-term clinical readouts in lung disease (AATD, CF), ophthalmology, oncology (NSCLC), and aesthetics, leverages increased R&D productivity, which could drive future revenue growth and diversify earnings beyond a single product. Favorable dynamics in global healthcare, such as greater willingness to reimburse curative, high-value genetic therapies and broadening awareness due to successful launches and patient outcomes, should support sustainable long-term revenue growth and premium pricing, boosting revenue visibility and potentially net margins.

Curious what justifies assigning that sort of upside to Krystal Biotech today? The narrative leans on sharp revenue expansion, rising margins and a future earnings multiple that assumes the pipeline matures as planned. Want to see which specific growth path and profitability profile are baked into that $385 figure? The full breakdown shows exactly how those moving parts are combined into a single fair value number.

Result: Fair Value of $385 (UNDERVALUED)

However, the Krystal Biotech story also carries execution risk, particularly related to VYJUVEK revenue concentration and the outcome of upcoming ophthalmology and respiratory trial readouts.

Another view on Krystal Biotech valuation

The first narrative suggests Krystal Biotech is about 10% undervalued at $346.58 versus a $385 fair value anchored in long term earnings forecasts. On current numbers though, the stock trades on a 42.5x P/E against a fair ratio of 37.9x and a US Biotechs average of 17.4x, with peers at 35.7x. That gap points to meaningful valuation risk if expectations ease or sector sentiment cools. How comfortable are you paying this premium for the story described above?

Next Steps

Feeling mixed about Krystal Biotech after all of this? Move quickly, review the full picture, and weigh both sides with the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Krystal Biotech?

If Krystal Biotech has sharpened your focus on opportunities, do not stop here. Broaden your watchlist with fresh ideas that could reshape your portfolio next.

• Target future growth by reviewing screener containing 17 high quality undiscovered gems that combine strong fundamentals with less crowded investor attention.
• Prioritise resilience by scanning 75 resilient stocks with low risk scores that score well on quality and lower risk factors.
• Strengthen your core holdings by checking the solid balance sheet and fundamentals stocks screener (50 results) that pair financial stability with solid underlying businesses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.